Jan 26, 2026 | Press Releases
Phio’s Presentation to take place on Wednesday January 28, 2026 at 9 AM ETKing of Prussia, Pennsylvania–(Newsfile Corp. – January 26, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company...
Jan 20, 2026 | Press Releases
Pathology data indicate 70% overall response rate for squamous cell carcinomas: 100% clearance in 10 out of 14 responders Favorable safety and tolerability at all dose escalations King of Prussia, Pennsylvania–(Newsfile Corp. – January 20, 2026) –...
Jan 15, 2026 | Press Releases
Registration Link for Phio’s Presentation on Thursday, January 22 at 1:45 PM ETKing of Prussia, Pennsylvania–(Newsfile Corp. – January 15, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company...
Dec 23, 2025 | Press Releases
Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania–(Newsfile Corp. – December 23, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...
Nov 25, 2025 | Press Releases
King of Prussia, Pennsylvania–(Newsfile Corp. – November 25, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology...
Nov 17, 2025 | Press Releases
Presenting INTASYL siRNA Drug TechnologyKing of Prussia, Pennsylvania–(Newsfile Corp. – November 17, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary...
